Yes, Opdualag Treats Unresectable or Metastatic Melanoma
Opdualag (nivolumab and relatlimab-rmbw) is FDA-approved for adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.[1] It combines PD-1 inhibition (nivolumab) with LAG-3 inhibition (relatlimab) to boost immune response against melanoma cells.
How Opdualag Works Against Melanoma
The dual immunotherapy blocks two checkpoints—PD-1 and LAG-3—on T-cells, preventing tumor evasion of the immune system. In the RELATIVITY-047 trial, Opdualag extended progression-free survival to a median of 10.1 months versus 4.6 months with nivolumab alone in first-line advanced melanoma.[1][2]
What Stages of Melanoma Does It Cover?
Approved specifically for unresectable (cannot be surgically removed) or metastatic (stage III or IV) melanoma. Not indicated for earlier resectable stages or adjuvant therapy post-surgery.[1]
Who Makes Opdualag and When Was It Approved?
Bristol Myers Squibb manufactures and markets it. FDA granted accelerated approval in March 2022, converted to full approval in the EU but remains accelerated in the US pending overall survival data.[1][3]
Common Side Effects in Melanoma Patients
Fatigue, rash, pruritus, diarrhea, and musculoskeletal pain occur in over 20% of patients. Severe immune-related events like colitis, hepatitis, or pneumonitis affect 10-15%; requires monitoring and possible steroids.[1]
How Does Opdualag Compare to Other Melanoma Immunotherapies?
| Therapy | Key Mechanism | PFS in 1L Metastatic Melanoma | OS Benefit |
|---------|---------------|-------------------------------|------------|
| Opdualag | PD-1 + LAG-3 | 10.1 months [2] | Pending full data |
| Keytruda (pembrolizumab) | PD-1 | 11.2 months (KEYNOTE-006) [4] | Yes |
| Opdivo (nivolumab) | PD-1 | 4.6 months [2] | Yes |
| Yervoy + Opdivo | CTLA-4 + PD-1 | 11.5 months (CheckMate 067) [5] | Yes |
Opdualag shows a favorable safety profile over CTLA-4 combos, with fewer discontinuations.[2]
When Does Opdualag's Patent Protection End?
Core composition-of-matter patents for relatlimab expire around 2035, with U.S. exclusivity until 2027 (pediatric) and potential extensions. No major challenges listed yet.[6]
Can Opdualag Treat Other Cancers?
Currently approved only for melanoma. Bristol Myers Squibb is testing it in non-small cell lung cancer, hepatocellular carcinoma, and esophageal cancer in ongoing trials.[3]
Sources
[1]: FDA Label for Opdualag
[2]: NEJM: RELATIVITY-047 Trial
[3]: BMS Opdualag Page
[4]: KEYNOTE-006 Results
[5]: CheckMate 067 Update
[6]: DrugPatentWatch: Opdualag Patents